Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4763681 | 0.75 | SNCA (0.33) | PIK3CDPIK3CAAAK1MAPK14 | |
| SCHEMBL4772120 | 0.69 | HTR2C (0.46) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 | |
| SCHEMBL24270120 | 0.68 | PDE3B (0.36) | PIK3CDPIK3CAPIK3CBPIK3CGMAPK14 | |
| SCHEMBL932928 | 0.67 | PIK3CD (0.45) | PIK3CDPIK3CAPIK3CBPIK3CGMAPK14 | |
| SCHEMBL771882 | 0.66 | CES2 (0.43) | MAPK14 | |
| SCHEMBL31706654 | 0.66 | DYRK1A (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 | |
| SCHEMBL15260158 | 0.66 | PIK3CA (0.39) | PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL24156076 | 0.66 | PIK3CD (0.40) | PIK3CDPIK3CAPIK3CBPIK3CGMAPK14 | |
| SCHEMBL967126 | 0.65 | MAPK14 (0.38) | PIK3CDPIK3CAMAPK14 | |
| SCHEMBL14853391 | 0.64 | PDE3B (0.41) | PIK3CDPIK3CAPIK3CBPIK3CGAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | PIK3CD 3238/4885PIK3CA 2853/4885PIK3CB 2927/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | PIK3CD 3004/4885PIK3CA 3278/4885PIK3CB 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.